This is a StreetInsider.com Premium Only Page

Allergan (AGN) –

Apr 11, 2024 07:00 AM Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

Apr 10, 2024 03:05 PM Form D Algernon Pharmaceuticals

Apr 10, 2024 06:25 AM Form 6-K AEGON LTD. For: Apr 10

Apr 9, 2024 06:10 AM Form 6-K AEGON LTD. For: Apr 09

Apr 4, 2024 09:49 AM Form IRANNOTICE AEGON LTD.

Apr 4, 2024 09:46 AM Form 6-K AEGON LTD. For: Apr 04

Apr 4, 2024 07:31 AM Form 20-F AEGON LTD. For: Dec 31

Apr 1, 2024 07:00 AM Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

Mar 27, 2024 12:04 PM Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Mar 19, 2024 07:11 AM Form 6-K AEGON LTD. For: Mar 19

Mar 1, 2024 10:42 AM Form 6-K AEGON LTD. For: Mar 01

Mar 1, 2024 06:09 AM Form 6-K AEGON LTD. For: Mar 01

Feb 22, 2024 04:16 PM ALAMO GROUP INC. ANNOUNCES RETIREMENT OF BOARD MEMBER, APPOINTMENT OF NEW BOARD CHAIR AND APPOINTMENT OF NEW DIRECTOR

Feb 9, 2024 12:59 PM Form SC 13G/A AEGON LTD. Filed by: DODGE & COX

Feb 8, 2024 12:27 PM Form SC 13G/A AEGON LTD. Filed by: DODGE & COX

Jan 31, 2024 07:00 AM Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

Jan 11, 2024 07:00 AM Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

Dec 29, 2023 06:44 AM Form SC 13D/A AEGON LTD. Filed by: AEGON LTD.

Dec 27, 2023 04:01 PM Algernon Pharmaceuticals Announces Closing of Private Placement

Dec 27, 2023 07:00 AM Algernon Pharmaceuticals Announces Increase to Private Placement

Dec 20, 2023 02:29 PM AM Best Affirms Credit Ratings of Members of Aegon Ltd.’s U.S. Subsidiaries

Dec 12, 2023 07:42 PM Algernon Pharmaceuticals Announces Private Placement

Dec 11, 2023 09:29 AM Form 6-K AEGON LTD. For: Dec 11

Nov 30, 2023 07:00 AM Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

Nov 22, 2023 07:00 AM Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Nov 9, 2023 11:17 AM Form 6-K AEGON LTD. For: Nov 09

Nov 9, 2023 02:00 AM Albert Benchimol to be nominated as non-executive member of the Board of Directors

Nov 8, 2023 07:00 AM Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

Oct 3, 2023 07:57 AM Form 6-K AEGON LTD. For: Oct 03

Oct 2, 2023 04:53 PM Form S-8 POS AEGON LTD.

Oct 2, 2023 09:16 AM Form 6-K AEGON LTD. For: Oct 02

Sep 30, 2023 10:28 AM Redomiciliation to Bermuda completed

Sep 29, 2023 02:35 PM Form 425 AEGON NV Filed by: AEGON NV

Sep 29, 2023 08:11 AM Form 6-K AEGON NV For: Sep 29

Sep 29, 2023 05:44 AM Extraordinary General Meeting approves first step in redomiciliation to Bermuda

Sep 19, 2023 04:57 PM Form 424B3 AEGON NV

Sep 15, 2023 04:27 PM Form 425 AEGON NV Filed by: AEGON NV

Sep 14, 2023 11:20 AM Form 425 AEGON NV Filed by: AEGON NV

Sep 13, 2023 05:17 PM Form 425 AEGON NV Filed by: AEGON NV

Sep 8, 2023 01:03 PM Form 425 AEGON NV Filed by: AEGON NV

Sep 6, 2023 07:00 AM Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Aug 21, 2023 11:29 AM Form SC 13D/A AEGON NV Filed by: AEGON NV

Aug 17, 2023 05:13 PM Form 425 AEGON NV Filed by: AEGON NV

Aug 17, 2023 05:12 PM Form 425 AEGON NV Filed by: AEGON NV

Aug 17, 2023 05:10 PM Form 425 AEGON NV Filed by: AEGON NV

Aug 17, 2023 05:07 PM Form 425 AEGON NV Filed by: AEGON NV

Aug 17, 2023 10:54 AM Form 424B3 AEGON NV

Aug 17, 2023 10:33 AM Form 6-K AEGON NV For: Aug 17

Aug 17, 2023 09:15 AM Form 6-K AEGON NV For: Jun 30

Aug 17, 2023 08:57 AM Form 6-K AEGON NV For: Aug 17